혈액 스크리닝 시장 규모 : 유형별, 기술별, 최종사용자별, 지역별, 범위 및 예측

Blood Screening Market Size And Forecast

The Blood Screening Market size was valued at USD 2.7 Billion in 2023 and is expected to reachUSD 5.4 Billion in 2031, at aCAGR of 8.6% over the forecast period of 2024 to 2031.

Blood screening is the process of analysing blood samples to identify infections, illnesses and disorders. It identifies viruses such as HIV, hepatitis and other blood-borne infections, ensuring blood transfusion safety and early detection in medical treatments and thereby contributing to overall public health and disease prevention initiatives.

Blood screening detects infectious disorders such as HIV, hepatitis and malaria, allowing for safe blood transfusions. It detects chronic disorders like diabetes and high cholesterol, helps with early cancer diagnosis, monitors organ function, and promotes preventative healthcare by detecting risk factors for numerous illnesses, thereby improving general public health and safety.

Future applications of blood screening will improve early disease identification, allowing for individualized treatment strategies for ailments such as cancer and cardiovascular disease. Advanced technology will improve the accuracy with which genetic markers and infections are identified, allowing for better preventive care, chronic condition monitoring and safer blood transfusions and organ transplantations.

Blood Screening Market Dynamics

The key market dynamics that are shaping the Blood Screening Market include:

Key Market Drivers:

Increasing Blood Donations:

A growing number of blood donations and transfusions worldwide is driving the demand for efficient blood screening methods.

Rising Prevalence of Infectious Diseases:

The increasing incidence of infectious diseases such as HIV, hepatitis, and Zika virus necessitates rigorous blood screening protocols.

Technological Advancements:

Innovations in blood screening technologies, including nucleic acid amplification tests (NAT) and next-generation sequencing (NGS), are enhancing the accuracy and efficiency of blood tests.

Government Initiatives:

Supportive government policies and funding for blood safety programs are propelling the market growth.

Public Awareness:

Increased public awareness about the importance of blood safety is contributing to the market expansion.

Key Challenge:

High Costs of Screening:

The high cost of advanced screening technologies can be a barrier for adoption, especially in developing countries.

Regulatory Stringency:

Stringent regulatory requirements and lengthy approval processes for new screening technologies can hinder market growth.

Limited Access in Low-Income Regions:

Limited infrastructure and resources in low-income regions restrict the implementation of advanced blood screening methods.

Key Trends:

Automation in Blood Screening:

The integration of automation in blood screening processes is improving throughput and reducing manual errors.

Adoption of Artificial Intelligence:

AI and machine learning are being increasingly adopted for data analysis and interpretation in blood screening, enhancing diagnostic accuracy.

Point-of-Care Testing:

The rise of point-of-care testing (POCT) for blood screening is providing quick and reliable results, particularly in remote and underserved areas.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Blood Screening Market Regional Analysis

Here is a more detailed regional analysis of the blood screening market:

North America

According to Verified Market Research, North America is expected to dominate the blood screening market.

This dominance is driven by a high demand for blood transfusions, advanced healthcare infrastructure, and the presence of established players like Grifols, Abbott Laboratories, and Bio-Rad Laboratories.

Additionally, stringent regulatory frameworks and public awareness about blood safety contribute to North America's leading position in the market.

Asia Pacific

According to Verified Market Research, Asia Pacific is fastest growing region in blood screening market.

The Asia Pacific region is expected to witness the highest growth rate in the blood screening market.

The expanding healthcare infrastructure, increasing blood donations, and rising prevalence of infectious diseases are driving the market growth.

Countries like China, India, and Japan are focusing on enhancing their blood screening protocols and adopting advanced technologies.

Blood Screening Market Segmentation Analysis

The Blood Screening Market is segmented on the basis of Type, Application and Geography.

Blood Screening Market, By Type

• Reagents & Kits
• Instruments
• Software & Services

Based on Type, the market is segmented into Reagents & Kits, Instruments and Software & Services. Reagents & kits accounted for the largest market share in the global blood screening market. The growing prevalence of infectious diseases and the rising need for safe blood transfusions have driven the demand for high-quality reagents and kits. These products are essential for detecting pathogens in donated blood, ensuring the safety and reliability of blood transfusions. As healthcare facilities and blood banks prioritize accuracy and efficiency in blood screening processes, the adoption of advanced reagents and kits is significantly increasing. This trend reflects the ongoing efforts to enhance blood safety and the overall quality of healthcare services.

Blood Screening Market, By Technology

• Nucleic Acid Testing (NAT)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Rapid Tests
• Western Blotting

Based on Technology, the market is segmented into Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests and Western Blotting. In the Blood Screening Market, Nucleic Acid Testing (NAT) is the dominant technology. NAT is highly favored for its ability to detect viral genetic material at an early stage, significantly reducing the window period during which infections may not be detected by traditional serological methods. This technology ensures a higher level of safety and reliability in blood screening processes, making it crucial for preventing the transmission of infectious diseases through blood transfusions.

Blood Screening Market, By End User

• Blood Banks
• Hospitals
• On the basis of End User, the market is divided into Blood banks and Hospitals. In the blood screening market, blood banks are the dominant end users. Blood banks play a critical role in ensuring the safety and availability of blood for transfusions. They employ rigorous blood screening protocols to detect infectious agents, thereby maintaining the highest standards of blood safety and mitigating the risk of transfusion-transmitted infections.

Blood Screening Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the Blood Screening Market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest market share in the global blood screening market. The region's dominance is attributed to the well-established healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Moreover, the increasing prevalence of chronic diseases and the rising number of surgical procedures requiring blood transfusions have further boosted the demand for blood screening in North America. The region's strong focus on blood safety, coupled with continuous advancements in screening technologies, ensures the growth and sustainability of the blood screening market.

Key Players

• The "Blood Screening Market" study report will provide valuable insight with an emphasis on the global market, including some of the major players in the industry such as
• Abbott Laboratories, Grifols, Bio-Rad Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Ortho Clinical Diagnostics, Becton Dickinson.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

• Blood Screening Market Recent Developments
• In March 2023, Abbott Laboratories introduced a new high-throughput screening system for detecting infectious diseases in donated blood.
• In August 2023, Roche Diagnostics launched a next-generation sequencing platform for comprehensive blood screening.
• In October 2023, Siemens Healthineers entered into a collaboration with a leading blood bank to implement advanced screening technologies.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD SCREENING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD SCREENING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD SCREENING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Software & Services

6 GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Nucleic Acid Amplification
• 6.3 ELISA
• 6.4 Rapid tests
• 6.5 NGS

7 GLOBAL BLOOD SCREENING MARKET, BY END USER

• 7.1 Overview
• 7.2 Blood Banks
• 7.3 Hospitals

8 GLOBAL BLOOD SCREENING MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL BLOOD SCREENING MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Grifols
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 F. Hoffmann-La Roche
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott Laboratories
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Biomerieux
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bio-Rad Laboratories, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Siemens Healthineers
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Ortho Clinical Diagnostics, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Thermo Fisher Scientific, Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Beckman Coulter
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Becton, Dickinson and Company
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research